Trials / Completed
CompletedNCT06169319
A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)
A Phase 2, Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 231 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Collagenase Clostridium Histolyticum (CCH) | Biologic: Intrafascial injection |
| BIOLOGICAL | Placebo | Intrafascial injection |
Timeline
- Start date
- 2024-01-03
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
- First posted
- 2023-12-13
- Last updated
- 2025-09-30
Locations
39 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06169319. Inclusion in this directory is not an endorsement.